Quick Answer
FILANA THERAPEUTICS, INC. reported Cash and Equivalents of $95.50 million for fiscal year 2025.
FILANA THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $95.50M | -25.7% |
| 2024 | $128.57M | +6.1% |
| 2023 | $121.14M | -39.7% |
| 2022 | $201.01M | -13.9% |
| 2021 | $233.44M | +149.6% |
| 2020 | $93.51M | +305.1% |
| 2019 | $23.08M | +16.5% |
| 2018 | $19.81M | +89.0% |
| 2017 | $10.48M | -36.9% |
| 2016 | $16.61M | -46.9% |
| 2015 | $31.30M | -22.9% |
| 2014 | $40.59M | -16.5% |
| 2013 | $48.59M | -1.6% |
| 2012 | $49.35M | -32.5% |
| 2011 | $73.14M | +1424.5% |
| 2010 | $4.80M | -86.6% |
| 2009 | $35.79M | -76.6% |
| 2008 | $153.16M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $106.08M | -28.8% | -5.6% |
| June 30, 2025 | $112.38M | -45.8% | -4.2% |
| March 31, 2025 | $117.33M | -5.5% | -8.7% |
| December 31, 2024 | $128.57M | +6.1% | -13.7% |
| September 30, 2024 | $148.98M | +4.7% | -28.1% |
| June 30, 2024 | $207.29M | +23.1% | +66.9% |
| March 31, 2024 | $124.17M | -33.8% | +2.5% |
| December 31, 2023 | $121.14M | -39.7% | -14.9% |
- FILANA THERAPEUTICS, INC. showed a decrease of -25.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, FILANA THERAPEUTICS, INC.’s cash and equivalents has declined by 37.6% (from $153.16 million to $95.50 million).
- The most recent figure is from FILANA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: